IDH1 and acute myeloid leukemia: On this foundation, an open-label, multicenter, phase Ib trial (NCT02677922) to evaluate safety and efficacy of combining ivosidenib with AZA in patients with newly diagnosed IDH1-mutated AML ineligible for intensive induction chemotherapy was performed [95].